Novel Pharmacological Approaches in Migraine Therapy
University of Calabria, Rende (Cosenza), Italy
September 19th-20th, 2024
Aula Magna
A Collaborative Scientific Initiative of
The University of Calabria, Rende (Cosenza), Italy,
The University Magna Graecia, Catanzaro, Italy,
Sant’Anna Institute, Kroton, Italy
Under the Auspices of
NEXTGENERATIONEU (NGEU) and the Ministry of University and Research (MUR), National Recovery and Resilience Plan (NRRP), project MNESYS (PE0000006)—A Multiscale integrated approach to the study of the nervous system in health and disease (DN. 1553 11.10.2022)
Italian Society of Pharmacology (SIF)
Italian Society of Neuroscience (SINS)
Italian Society for the Study of Headache (SISC)
Italian Society of Neurological Rehabilitation (SIRN)
Italian Society of Child and Adolescent Neuropsychiatry (SINPIA)
Scientific Program
Thursday, September 19th, 2024
15:00 – 15:30 Registration
15:30 – 16:45 Welcome address and meeting rationale
Giacinto Bagetta, University of Calabria (Rende, Cosenza) & Giovambattista De Sarro, University Magna Graecia (Catanzaro)
Francesco Scarcello, viceRector University of Calabria (Rende, Cosenza)
Maria Luisa Panno, Head of Department of Pharmacy, Health Science
and Nutrition, University of Calabria (Cosenza)
Sebastiano Andò, Emeritus of General Pathology, University of Calabria (Cosenza)
Giuseppe Cirino, President of Italian Society of Pharmacology (Naples)
Carmela Matrone, President of Italian Society of Neuroscience, (Milan)
16.45 – 17:00 Introduction of Lectio Magistralis speaker
Damiana Scuteri PhD (University Magna Graecia, Catanzaro)
17:00 – 17:45 Lectio Magistralis
Philip R. Holland, Reader of Neuroscience (PI Headache Group,
Kings College, London)
Understanding the Pathophysiology of Migraine to Develop New Therapies: Bench to Bedside
17.45 – 18:00 Introduction of Lectio Magistralis speaker
Damiana Scuteri PhD (University Magna Graecia, Catanzaro)
18:00 – 18:45 Lectio Magistralis
Stephen D. Silberstein, Professor of Neurology (Director, Headache Center, Sidney Kimmel Medical College Thomas Jefferson University, Philadelphia, PA USA)
Title: Cannabinoids and migraine
18:45 – 19:00 Welcome cocktail
Friday, September 20th, 2024
Introduction of Keynote speaker
Pierluigi Nicotera (Bonn)
9:00 – 9:30 Keynote speaker
Oliver J Dolly (Dublin)
Neurobiology and therapeutic application of botulinum toxin in migraine
9:30 – 11:00
1st COMMUNICATIONS SESSION: Basic Research in Head Pain
Chairpersons: Monica Di Luca (Milan) & Gary Lawrence (Dublin)
Pierangelo Geppetti (Florence)
Transient receptors in head pain mechanisms
Stefania Ceruti (Milan)
Glia activation in migraine preclinical setting
Carmela Belardo (Naples)
Social isolation and head pain
Luca Gallelli (Catanzaro)
New non-pharmacological perspectives for head pain management
11:00-11.30 Coffee break
Introduction of Keynote speaker
Giuseppe Pignataro (Naples)
11:30 – 12:00 Keynote speaker
Cristina Tassorelli (Pavia)
The changing landscape of migraine treatment: a revolution in 5 years
12:00 – 13:30
2nd COMMUNICATIONS SESSION: Clinical aspects of migraine
Chairpersons: Paola Sacerdote (Milan) & Lucio Annunziato (Naples)
Rossella E Nappi (Pavia)
Linking sex hormones to migraine: theories and practice
Simona Sacco (L’Aquila)
Medication overuse headache (MOH) diagnosis and management
Umberto Aguglia (Catanzaro)
Migraine and Epilepsy: a diagnostic challenge
Giangennaro Coppola (Salerno), Francesca Operto (Catanzaro)
Classification of headaches in developmental age: diagnosis and treatment
13:30-15:00 Lunch break and Poster presentation
Introduction of Keynote speaker
Sabatino Maione (Naples)
15:00 – 15:30 Keynote speaker
Dimos-Dimitrios Mitsikostas (Athens)
Ditans and 5-HT1F receptor in migraine
15:30 – 16:30
3rd COMMUNICATIONS SESSION: From Bench to Bedside Research in Migraine Therapy
Chairpersons: Giorgio Racagni (Milan) & Annalisa Capuano (Naples)
Alberto Chiarugi (Florence)
Neuropeptide receptors involved and potentially involved in migraine pathogenesis
Marina De Tommaso (Bari)
Exploitation of disease modifying properties of anti-CGRP/R mAbs
Damiana Scuteri (Catanzaro)
Real world evidence in favor of anti-CGRP/R mAbs and beyond
16:30 – 17:00 Coffee break
Introduction of Keynote speaker
Gennarina Arabia (Catanzaro)
17:00 – 17:30 Keynote speaker
Paolo Martelletti (Rome)
Public health issues in current migraine management
17:30-18:00
4th COMMUNICATIONS SESSION: Regulatory Aspects of Migraine therapy
Chairpersons: Giovambattista De Sarro (Catanzaro) & Patrizia Popoli (Rome)
Domenico Conforti (Rende, Cosenza) & Rosario Iannacchero (Catanzaro)
The regional network for head pain management: project Alcmeone AI role in diagnostics and therapy
Rita Scarpelli (Catanzaro)
Regional endorsement of economic burden for novel therapies
Antonio Leo & Francesca Bosco (Catanzaro)
Patterns of active pharmacovigilance of novel therapies
Patrizia Popoli (Rome)
Independent assessment of novel therapies for efficacy and affordability
Poster Communications
Presidents
Giacinto Bagetta (Rende, Cosenza), Maria Tiziana Corasaniti (Catanzaro)
Giovambattista De Sarro (Catanzaro)
Organizing Committee
Antonio Leo (Catanzaro),
Damiana Scuteri (Catanzaro)
Meeting rationale
Migraine is among the most disabling forms of primary headache, endowed with a serious social impact and ranking as one of the top causes of years lived with disability worldwide, particularly in people under fifty. It is characterized by recurrent attacks of moderate to severe throbbing and pulsating pain on one side of the head and untreated attacks last from four to 72 hours. Pain is caused by the activation of nerve fibers within the wall of brain blood vessels traveling inside the meninges. Other common symptoms include increased sensitivity to light, noise, and odors, nausea, vomiting. Clustered populations suffering from the disease leave open the role of endogenous as well as exogenous triggers helping the definition of diverse pathophysiological paradigms for the exercise of research. Indeed, in the past, this clinical field has been characterized by poor knowledge on the pathophysiology of the disease leading to preventive approaches borrowed from drugs originally developed for other therapeutic indications, with consequent limited efficacy and endowed with unacceptable level of side effects causing scarce adherence. At variance with this situation, more than 35 years of pharmacological research effort have established a strong rational basis upon which the actually available disease modifying drugs have been developed. In fact, systematic investigations on calcitonin gene–related peptide (CGRP) have established its fundamental role in the pathophysiology of migraine through nociceptive mechanisms in the trigeminovascular system. The role of CGRP in migraine can be now considered clearly demonstrated also at the level of clinical trials of small-molecule CGRP-receptor antagonists in acute migraine and it is further supported in trials of biotech drugs including onabotulinum toxin A and monoclonal antibodies targeting the CGRP pathway in episodic and chronic migraine. Whilst all this will have a great impact on the frequency and management of acute manifestations as well as the whole history of chronic migraine, new and old questions remain to be answered. In this new scenario, in fact, several pathophysiological as well as therapeutic and regulatory questions remain open. The organizers of this meeting intended to contribute by calling basic and clinical scientists, among the most knowledgeable at the national and international level, as well as national and regional regulators to provide postgraduate students, young researchers and clinicians with their most up to date view on these matters.
Contact us
Executive Secretariat: Dott. Giuseppe Oliva
Department of Pharmacy, Health Sciences and Nutrition, University of Calabria, 87036 Rende, Cosenza, Italy; giuseppe.oliva@unical.it